Brian Wolpin

Company: Dana-Farber Cancer Institute & Harvard Medical School

Job title: Robert T. & Judith B. Hale Chair in Pancreatic Cancer & Professor of Medicine

Seminars:

Panel Discussion: Reviewing the Toxicity Concerns with Multi-Inhibitors & Strategies to Pre-Emptively Address Them 11:15 am

PAN-RAS inhibitors are known to be mutations and often isofrom agnostic. Due to their unique mechanisms of action, they often target wild-type RAS as well, resulting in normal cell toxicity. Preemptively dealing with these foreseen negative effects is important to ensure that PAN-inhibitors and multi-inhibitors can reach their full potential as personalized cancer treatments. Reviewing…Read more

day: Day Two Track B AM

RMC-6236, a Novel, First in Class, Tricomplex RASMULTI(ON) Inhibitor: Preliminary Clinical Results & Learnings 9:00 am

Basis of inhibiting the RAS(ON) form of multiple RAS mutational drivers Initial tolerability profile during phase 1 dose escalation and potential mechanistic explanation Preliminary anti-tumor activity in RASMUT pancreatic cancer and non-small cell lung cancerRead more

day: Conference Day Two